There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We are also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
Tony Wood
Chief Scientific Officer
We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.
We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
Our R&D investment in 2022
£5.5bn
An outstanding R&D team of
15k
Our pipeline
As a global biopharma leader, we invest heavily in our industry-leading pipeline of new products that help us to get ahead of disease together.
the number of assets in phase III clinical development during the last 5 years
Global Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, oncology and immunology. We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
